Projects
ADAPT SMART
Accelerating early access to innovative medicines for appropriate patient groups
The IMI ADAPT SMART project launched in September 2015. It is an enabling platform that supports activities related to Medicines Adaptive Pathways to Patients (MAPPs) within the Innovative Medicines Initiative (IMI). MAPPs seek to foster access to beneficial treatments for appropriate patient groups at the earliest appropriate stage in the lifecycle.
€3.1 M
funding from IMI2 and EFPIA
32
international partners
About ADAPT SMART
The ADAPT SMART* platform allows for all stakeholders to coordinate MAPP-related activities and to distribute key findings. It also aims to identify the scientific challenges and opportunities that might arise during the adoption of MAPPs. Outcomes from the consortium will inform future research agendas and provide a basis for discussing approaches to the implementation of MAPPs. Visit the ADAPT SMART website for more information.
*Accelerated Development of Appropriate Patient Therapies: a Sustainable, Multi-stakeholder Approach from Research to Treatment-outcomes.
Coordinating multi-stakeholder dialogue
The project reaches out to all stakeholders involved in the pathway of a medicine, from development to patient. Its international consortium brings together 32 partners, including the European Medicines Agency which fulfills the project leader role. Lygature coordinates the consortium, with roles and responsibilities that include:
- Program management. Lygature is responsible for overall program management, with the goal of supporting and monitoring effective execution of the work plan, including control of deliverables, milestones, and budgets.
- Coordination and leadership. Lygature is a co-lead in Work Package 2 of the project. This Work Package develops a roadmap for the MAPPs process for products, involving all phases of development and licensing as well as all relevant stakeholders (e.g. HTA, payers, clinical practice).
- Trusted partner. As an independent partner, Lygature safeguards different public and private interests from the proposal phase to the results phase, ensuring strict confidentiality.
ADAPT SMART is the first project under IMI to bring together, within a strategic policy, project stakeholders that include industry, regulatory authorities, patient organizations, physicians, health technology assessment institutions, and payers. It is a prime example of the Lygature mission to coordinate and combine complementary areas of expertise, and potentially different interests, in order to accelerate access to beneficial treatment options for appropriate patient groups.
Lygature together with
Abbvie, Amgen, Astellas, AstraZeneca, Bayer HealthCare, Boehringer-ingelheim, Bristol-Myers Squibb, Casmi, European Federation of Pharmaceutical Industries and Associations, European Medicines Agency, European Patients Forum, EURORDIS, GlaxoSmithKline, Haute Autorité de Santé, Ipsen, Janssen, Lilly, H. Lundbeck A/S, Lysogene, Merck KGaA, MIT NEWDIGS, MSD, NICE, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi, Sundheds Styrelsen, UCB, Zorginstituut Nederland
Acknowledgement of support
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115890. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
Project updates
-
Podcast: "The Evolution of MAPPS"
On 17 February, ADAPT SMART had a discussion with Professor Hans-Georg Eichler, Senior Medical Officer EMA and ADAPT SMART project leader to find out the evolution of MAPPs in Europe and Internationally.
-
Press release: IMI’s ADAPT SMART Kick-Starts 2017 by Putting Stakeholders at the Centre
(January 18, 2017 – London): ADAPT SMART’s General Assembly, held at the European Medicines Agency (EMA), agrees to focus its final year on incorporating stakeholder feedback into the development of Medicines Adaptive Pathways to Patients (MAPPs) tools and methodologies.
With growing international interest and visibility in the final year of the consortium, ADAPT SMART members have agreed to redouble their efforts to collaborate with key stakeholder groups and incorporate their feedback into the deliverables during the calendar year of 2017.
MAPPs aims to foster access to beneficial treatments for specific, well-defined, patient groups at the earliest appropriate time in the product life-span in a sustainable and affordable fashion. Under the Innovative Medicines Initiative (IMI2), the ADAPT SMART consortium (a Sustainable, Multi-stakeholder Approach from Research to Treatment-outcomes) enables coordination of MAPPs activities, supporting investigation of methodologies and dialogue to develop workable concepts.
-
ADAPT SMART glossary published
The ADAPT SMART glossary provides working definitions for common terms relevant for the consortium and includes references. Read more